首页 | 本学科首页   官方微博 | 高级检索  
     


Mexiletine or catheter ablation after amiodarone failure in the VANISH trial
Authors:Marc W. Deyell MD MSc  Christian Steinberg MD  Steve Doucette MSc  Ratika Parkash MD MS  Isabelle Nault MD  Chris Gray MD  Vidal Essebag MD PhD  Martin Gardner MD  Laurence D. Sterns MD  Jeff S. Healey MD  Tomasz Hruczkowski MD  Lena Rivard MD  Peter Leong‐Sit MD  Pablo B. Nery MD  John L. Sapp MD
Affiliation:1. Heart Rhythm Services, Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada;2. Institut Universitaire de Cardiologie et Pneumologie de Québec, Universite Laval, Quebec City, Quebec, Canada;3. Department of Medicine, QEII Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada;4. McGill University Health Centre and H?pital Sacré‐Coeur de Montréal, Montreal, Quebec, Canada;5. Royal Jubilee Hospital, Victoria, British Columbia, Canada;6. Population Health Research Institute, Hamilton, Ontario, Canada;7. Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada;8. Institut de Cardiologie de Montréal, Montreal, Quebec, Canada;9. Heart Rhythm Service, University Hospital, Western University, London, Ontario, Canada;10. University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Abstract:
Keywords:amiodarone  catheter ablation  ischemic heart disease  mexiletine  ventricular tachycardia
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号